Geoffrey Chan
About Geoffrey Chan
Geoffrey Chan is the Executive Director at Bristol Myers Squibb and an Attending Physician at Philadelphia Veterans Administration Medical Center, with extensive experience in oncology drug development.
Company
Geoffrey Chan currently holds the position of Executive Director at Bristol Myers Squibb. In this role, he leads the development of cutting-edge cancer therapies and oversees the strategic direction of clinical projects. Under his leadership, initiatives such as the development of Reblozyl, which began in 2022, have been at the forefront.
Title
Geoffrey Chan serves as Executive Director at Bristol Myers Squibb and also performs duties as an Attending Physician in Hematology/Oncology at the Philadelphia Veterans Administration Medical Center. This dual role allows him to combine his clinical practice with his extensive expertise in drug development.
Education and Expertise
Geoffrey Chan has an extensive educational background, holding an MBA in Entrepreneurship from West Chester University of Pennsylvania, a Fellowship in Hematology and Oncology from Tufts Medical Center, an MD from both Brown Medical School and Geisel School of Medicine at Dartmouth, and a B.A. in Economics from Boston College. His deep understanding of both clinical and entrepreneurial aspects of medicine positions him uniquely in the field of oncology drug development.
Professional Background
Geoffrey Chan's career includes key roles such as Senior Director, Clinical Development Oncology at Pfizer and Director positions at Novartis, GSK, and Tufts-New England Medical Center. At Pfizer, Chan worked for six years in Collegeville, focusing on developing oncology therapies. His prior experience at GSK, spanning eight years, and brief tenure at Novartis further honed his skills in clinical development. He also served as an Assistant Professor of Medicine at Tufts-New England Medical Center for five years.
Achievements
Geoffrey Chan has a track record of successfully bringing a dozen new oncology indications to market across multiple regions, including the US, Europe, Canada, and Japan. His expertise in designing and executing global registration trials for monoclonal antibodies and small molecules is notable. He has managed small single arm studies to support accelerated and conditional approvals. In his current role, he leads a team focused on training the next generation of drug developers and aims to achieve Level Five Leadership, blending personal humility with professional will.